互聯藥物輸送設備市場規模、佔有率和成長分析（按產品類型、技術、應用、最終用戶和地區分類）—產業預測，2026-2033年

預計到 2024 年，連網藥物輸送設備市場規模將達到 74.7 億美元，到 2025 年將達到 92.9 億美元，到 2033 年將達到 529.2 億美元，在預測期（2026-2033 年）內，複合年成長率將達到 24.3%。

全球互聯藥物輸送設備市場正經歷顯著成長，這主要得益於數位健康解決方案的日益普及和個人化醫療需求的不斷成長。這些設備可為患者、醫療服務提供者和看護者提供即時數據追蹤、提醒和通知，有助於改善藥物管理和提升患者療效。物聯網、人工智慧和雲端運算等先進技術的整合正在透過增強患者參與度和實現遠端監測來改變醫療保健格局。隨著全球醫療系統採用數位轉型策略並持續優先考慮以患者為中心的護理，該市場已做好充分準備迎接顯著擴張，這反映了醫療服務模式向更有效率、更有效的轉變。

互聯藥物輸送設備市場促進因素

互聯藥物輸送設備市場的主要促進因素是對互聯個人化醫療解決方案日益成長的需求。這些創新設備具有許多優勢，包括遠端患者監護、即時數據採集和提高用藥依從性。它們使醫療專業人員能夠有效追蹤患者的健康狀況，調整治療方案，並提供個人化護理。將互聯技術融入藥物輸送系統，可增強患者參與度，並有助於改善治療效果。此外，慢性病發病率的上升以及對先進藥物輸送系統的需求，也是推動該市場成長的關鍵因素。

互聯藥物傳輸設備市場面臨的限制

互聯藥物傳輸設備市場面臨的一大挑戰是這些先進技術相關的高成本。無線連接和高級數據管理系統等功能的加入顯著提高了設備的價格。這一經濟障礙阻礙了設備的廣泛應用，尤其是在資源匱乏地區和發展中地區，預算限制是關鍵考慮因素。在某些患者群體和醫療服務提供者中，互聯藥物輸送設備的普及仍然受到價格和可及性問題的限制。解決這些成本相關的障礙，提高這些創新解決方案的可負擔性，對於促進更廣泛的接受度和刺激市場成長至關重要。

互聯藥物傳輸設備市場趨勢

互聯藥物輸送設備市場正呈現出顯著的趨勢，即整合先進的數位技術。尤其是在呼吸治療領域，智慧吸入器和其他連網設備的使用量激增。這些創新解決方案配備感測器和無線連接功能，能夠全面監測患者的用藥依從性、使用模式和劑量準確性。行動應用程式可為患者提供即時回饋和個人化建議，從而增強患者參與自身健康管理的積極性和自主性。這種向數據驅動型解決方案的轉變不僅改善了治療效果，還促進了更積極主動的患者照護模式，最終推動了互聯藥物輸送設備市場的成長。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 技術進步
• 監管環境
• 專利分析
• 案例研究
• Start-Ups分析

全球互聯藥物輸送設備市場規模（按產品類型和複合年成長率分類）（2026-2033 年）

• 連接式吸入器
  • 定量吸入器（MDI）
  • 乾粉吸入器（DPI）
• 網路注射裝置
  • 可連接式自動噴射器
  • 可連接的筆式射出器
  • 連網穿戴注射器
• 網路監控設備
  • 智慧藥丸
  • 智慧型貼片

全球互聯藥物輸送設備市場規模（依技術及複合年成長率分類）（2026-2033 年）

• Bluetooth
• Wi-Fi
• 近距離場通訊（NFC）
• 其他

全球互聯藥物輸送設備市場規模（按應用及複合年成長率分類）（2026-2033 年）

• 糖尿病
  • 胰島素給藥
• 氣喘和慢性阻塞性肺病（COPD）
  • 支氣管擴張劑給藥
• 循環系統疾病
  • 抗凝血劑給藥
• 其他
  • 荷爾蒙補充療法
  • 疼痛管理

全球互聯藥物輸送設備市場規模（按最終用戶分類）及複合年成長率（2026-2033 年）

• 醫院
  • 大型醫院
  • 中小型醫院
• 居家醫療環境
  • 個別患者
  • 看護者
• 診所
  • 專科診所
  • 一般診所

全球互聯藥物輸送設備市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2021-2023年營收年比比較

主要企業簡介

• Findair Sp. z oo（Poland）
• BIO CORP（France）
• Teva Pharmaceuticals Industries Ltd（Israel）
• Adherium Limited（New Zealand）
• West Pharmaceutical Services Inc.（USA）
• Aptar Pharma（USA）
• Ypsomed AG（Switzerland）
• Phillips-Medisize（USA）
• H&T Presspart Manufacturing Ltd（UK）
• Cohero Health, Inc.（USA）
• 3M Company（USA）
• Becton, Dickinson and Company（USA）
• Merck KGaA（Germany）
• Novartis AG（Switzerland）
• Johnson & Johnson（USA）
• AstraZeneca（UK）
• GlaxoSmithKline plc（UK）
• Pfizer Inc.（USA）
• Sanofi SA（France）
• F. Hoffmann-La Roche Ltd（Switzerland）

結論與建議

Connected Drug Delivery Devices Market size was valued at USD 7.47 Billion in 2024 and is poised to grow from USD 9.29 Billion in 2025 to USD 52.92 Billion by 2033, growing at a CAGR of 24.3% during the forecast period (2026-2033).

The global connected drug delivery devices market is witnessing notable growth, fueled by the rising adoption of digital health solutions and the demand for personalized healthcare. These devices provide real-time data tracking, along with reminders and notifications for patients, healthcare providers, and caregivers, which facilitates improved medication management and enhances patient outcomes. The incorporation of advanced technologies such as IoT, AI, and cloud computing is transforming the healthcare landscape by boosting patient engagement and enabling remote monitoring. As healthcare systems globally continue to adopt digital transformation strategies and emphasize patient-centric care, the market is well-positioned for significant expansion, reflecting a shift towards more efficient and effective healthcare delivery models.

Top-down and bottom-up approaches were used to estimate and validate the size of the Connected Drug Delivery Devices market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Connected Drug Delivery Devices Market Segments Analysis

Global Connected Drug Delivery Devices Market is segmented by product type, technology, application, end-user and region. Based on product type, the market is segmented into connected inhalers, connected injection devices and connected monitoring devices. Based on technology, the market is segmented into bluetooth, wi-fi, near field communication (NFC) and others. Based on application, the market is segmented into diabetes, asthma & COPD, cardiovascular diseases and other. Based on end-user, the market is segmented into hospitals, homecare settings and clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Connected Drug Delivery Devices Market

A significant driver of the connected drug delivery devices market is the growing need for personalized healthcare solutions that are interconnected. These innovative devices provide numerous advantages, including the capability for remote patient monitoring, real-time data collection, and enhanced medication adherence. They empower healthcare providers to effectively track patient health, modify treatment plans, and offer tailored care. The incorporation of connected technology into drug delivery systems bolsters patient engagement and fosters improved treatment outcomes. Furthermore, the rising incidence of chronic illnesses and the demand for sophisticated drug delivery systems play a crucial role in fueling the growth of this market.

Restraints in the Connected Drug Delivery Devices Market

A prominent challenge facing the connected drug delivery devices market is the elevated costs linked to these advanced technologies. The incorporation of features such as wireless connectivity and sophisticated data management systems significantly raises the prices of these devices. This financial barrier hinders widespread adoption, especially in low-resource settings and developing regions, where budget constraints are a critical consideration. Affordability and accessibility issues continue to restrict the uptake of connected drug delivery devices among specific patient demographics and healthcare providers. To foster broader acceptance and stimulate market growth, it will be crucial to address these cost-related obstacles and enhance the affordability of these innovative solutions.

Market Trends of the Connected Drug Delivery Devices Market

The Connected Drug Delivery Devices market is witnessing a significant trend towards the integration of advanced digital technologies, particularly the surge in the use of smart inhalers and other connected devices for respiratory therapies. These innovative solutions, equipped with sensors and wireless connectivity, facilitate comprehensive monitoring of medication adherence, usage patterns, and dosage accuracy. By harnessing mobile applications, patients can receive real-time feedback and personalized insights, enhancing their engagement and empowerment in managing their health. This shift towards data-driven solutions not only improves treatment outcomes but also fosters a more proactive approach to patient care, ultimately driving the market growth for connected drug delivery devices.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technological Advancement
• Regulatory Landscape
• Patent Analysis
• Case Studies
• Startup Analysis

Global Connected Drug Delivery Devices Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Connected Inhalers
  • Metered Dose Inhalers (MDIs)
  • Dry Powder Inhalers (DPIs)
• Connected Injection Devices
  • Connected Auto-Injectors
  • Connected Pen Injectors
  • Connected Wearable Injectors
• Connected Monitoring Devices
  • Smart Pills
  • Smart Patches

Global Connected Drug Delivery Devices Market Size by Technology & CAGR (2026-2033)

• Market Overview
• Bluetooth
• Wi-Fi
• Near Field Communication (NFC)
• Others

Global Connected Drug Delivery Devices Market Size by Application & CAGR (2026-2033)

• Market Overview
• Diabetes
  • Insulin Delivery
• Asthma & COPD
  • Bronchodilator Delivery
• Cardiovascular Diseases
  • Anticoagulant Delivery
• Other
  • Hormone Replacement Therapy
  • Pain Management

Global Connected Drug Delivery Devices Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals
  • Large Hospitals
  • Small And Medium-Sized Hospitals
• Homecare Settings
  • Individual Patients
  • Caregivers
• Clinics
  • Specialty Clinics
  • General Clinics

Global Connected Drug Delivery Devices Market Size & CAGR (2026-2033)

• North America (Product Type, Technology, Application, End-User)
  • USA
  • Canada
• Europe (Product Type, Technology, Application, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Technology, Application, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Technology, Application, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Technology, Application, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Findair Sp. z o. o. (Poland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BIO CORP (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceuticals Industries Ltd (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adherium Limited (New Zealand)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• West Pharmaceutical Services Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aptar Pharma (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ypsomed AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Phillips-Medisize (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• H&T Presspart Manufacturing Ltd (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cohero Health, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• 3M Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations